English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

There were an estimated 72.570 new cases and 15.210 deaths from bladder cancer in 2013. It represents 4.4% of all new cancer cases in the U.S.2. According to NCI Cairo, the leading cancers in Egyptian patients are the urinary bladder (32.67%)2. The National cancer registry in Egypt recorded a lower incidence, In Aswan 2008, bladder cancer accounted for 7.6% of total cancer cases. While in El-Minia 2009, 9.2% of total cancer cases, In Damietta 2010, bladder cancer reported a percentage of 5.7% of total cancer cases and it accounted as third most common cancer3. In Ain Shams University Hospitals Bladder cancer accounted for 5.2% of total patients and described as the fifth most common cancer4. Egyptian males have the highest mortality rates (16.3 per 100,000), which is twice as high as the highest rates in Europe (8.3 in Spain and 8.0 in Poland) and over 4 times higher than that in the United States5.

Docetaxel as second line after failure of gemcitabine/cisplatin regimen in advanced and/or metastatic urinary bladder cancer patients in Egypt